COMMUNIQUÉS West-GlobeNewswire

First-of-its-Kind Multicenter Study Demonstrates Utility of Monopoint System in Procedures to Treat Idiopathic Intracranial Hypertension
19/03/2025
Monopoint system enables rapid access to the venous system Research to be presented at SNIS Cerebral Venous and CSF Disorders Summit SAN MATEO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a [...]
NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th
19/03/2025
Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, [...]
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
19/03/2025
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Treatment with investigational OAV101 IT led to statistically [...]
Lipozem Reviews (Is It Safe And Legit To Use?) Ingredients, Side Effect Complaints, And Weight Loss Benefits!
19/03/2025
LAKELAND, Fla., March 19, 2025 (GLOBE NEWSWIRE) -- Lipozem is a weight loss supplement crafted to support burning fat without causing adverse or side effects. It contains carefully selected ingredients that activate [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
19/03/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 19 MARCH 2025 at 14.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Lirum Therapeutics Invited to Present at Prestigious Gordon Research Conference
19/03/2025
New York, NY, March 19, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that the [...]
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session
19/03/2025
Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: [...]
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
19/03/2025
Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near- [...]
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference
19/03/2025
ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high [...]
FDA Clears Magstim Transcranial Magnetic Stimulation System for U.S. Adolescent Patient Treatment
19/03/2025
Adolescent patients ages 15-21 can now receive non-invasive TMS for treatment of major depressive disorder (MDD)* MINNEAPOLIS, March 19, 2025 (GLOBE NEWSWIRE) -- Major depression impacts more than 5 million U.S. [...]
FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON BINDING AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.
19/03/2025
MINNEAPOLIS, MN, March 19, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), announces that it has signed a non-binding agreement to acquire Vector Biosource Inc. (“Vector”). Vector [...]
Organovo Announces Reverse Stock Split
19/03/2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today [...]
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
19/03/2025
TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, [...]
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
19/03/2025
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat [...]
Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program
19/03/2025
ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA highlighted [...]
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
19/03/2025
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: [...]
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
19/03/2025
CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development [...]
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
19/03/2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
19/03/2025
Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice Conference Dosing of first patient in THRIVE-3 registrational trial of IV [...]

Pages